Nebenwirkungen · Wegovy
Wegovy 0.25 mg solution for injection in pre-filled pen Wegovy 0.5 mg solution for injection in pre-filled pen Wegovy 1 mg solution for injection in pre-filled pen Wegovy 1.7 mg solution for injection in pre-filled pen Wegovy 2.4 mg solution for injection in pre-filled pen Wegovy 7.2 mg solution for injection in pre-filled pen Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen Wegovy 1 mg FlexTouch solution for injection in pre-filled pen Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen Wegovy 0.25 mg solution for injection in pre-filled syringe Wegovy 0.5 mg solution for injection in pre-filled syringe Wegovy 1 mg solution for injection in pre-filled syringe Wegovy 1.7 mg solution for injection in pre-filled syringe Wegovy 2.4 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 12
HOS-147322 · Präparat HOS-099634
Immunogenicity Consistent with the potentially immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide. The proportion of patients testing positive for anti-semaglutide antibodies at any time post-baseline was 2.9 – 10.9% for semaglutide 2.4 mg and 15.3% for semaglutide 7.2 mg. No patients had anti-semaglutide neutralising antibodies or anti-semaglutide antibodies with endogenous GLP-1 neutralising effect. During treatment, high semaglutide concentrations might have lowered the sensitivity of the assays, hence the risk of false negatives cannot be excluded. However, in subjects testing positive for antibodies during and after treatment, the presence of antibodies was transient and with no apparent impact on efficacy and safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage 60ed52d6f87caf1ee18aa136028a2dd517ece930d527dbda25d66f4a91108430 · Zeichen 7961–8789 im Abschnitt